title: New Combined Medical Treatment With Etilefrine and Octreotide for Chylothorax After Esophagectomy: A Case Report and Review of the Literature.
abstract: Postoperative chylothorax is a rare but well-known complication of general thoracic surgery. Medical treatment of chylothorax was reported in the past, but there is still considerable controversy on the appropriate management strategies.Two patients with esophageal cancer underwent esophagectomy, 2-field lymph node dissection, and resection of thoracic duct together with ileocolic reconstruction via the retrosternal route at our hospital. Chylothorax developed on the 32nd postoperative day (POD) in 1 patient and the 12th POD in the other, manifesting as a change in the character of thoracic drainage to turbid white. Both were immediately started on octreotide (300 μg/ day) and etilefrine (120 mg/day). When the amount of pleural effusion decreased to <50 mL/day, we performed pleurodesis with Picibanil (OK432). Thereafter, the patients gradually made satisfactory progress and resumed oral food intake, and the thoracotomy tubes were eventually removed. They have remained recurrence-free at the time of writing.In this report, we demonstrated the clinical efficacy of etilefrine for the management of postesophagectomy chylothorax. New medical treatment options for this condition are now broad and the usefulness of combined therapy consisting of a sclerosing agent, etilefrine, and octreotide is underscored, regardless of the status of the thoracic duct.
authors.affiliation: From the Department of Gastroenterological Surgery (YO, MU, SH, TT, HU), and Department of Gastroenterology (TI), Toranomon Hospital, Tokyo, Japan.
authors.forename: Yu
authors.initials: Y
authors.lastname: Ohkura
authors.forename: Masaki
authors.initials: M
authors.lastname: Ueno
authors.forename: Toshiro
authors.initials: T
authors.lastname: Iizuka
authors.forename: Shusuke
authors.initials: S
authors.lastname: Haruta
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Tanaka
authors.forename: Harushi
authors.initials: H
authors.lastname: Udagawa
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002916:Chylothorax / Q000188:drug therapy* / Q000209:etiology*; D004359:Drug Therapy, Combination; D004938:Esophageal Neoplasms / Q000601:surgery*; D016629:Esophagectomy / Q000009:adverse effects*; D005039:Etilefrine / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000008:administration & dosage / Q000627:therapeutic use*; D010844:Picibanil / Q000627:therapeutic use; D010996:Pleural Effusion / Q000628:therapy; D018700:Pleurodesis / Q000379:methods
chemical_list: D000970:Antineoplastic Agents; D010844:Picibanil; D015282:Octreotide; D005039:Etilefrine